S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer

Breast Cancer Clinical Trial

Official title:

Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes Phase III

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00005983
• Other study ID #: CDR0000067971
• Secondary ID: U10CA032102S9927
• Status: Terminated
• Phase: Phase 3
• First received: July 5, 2000
• Last updated: January 22, 2013
• Start date: June 2000
• Est. completion date: March 2005

Study information

• Verified date: January 2013
• Source: Southwest Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether mastectomy, chemotherapy, and/or hormone therapy are more effective with or without radiation therapy in treating breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of mastectomy, chemotherapy, and/or hormone therapy with or without radiation therapy in treating women who have stage II breast cancer.

Description:

OBJECTIVES:

• Compare overall and disease-free survival in women with stage II breast cancer with one to three positive nodes treated with radiotherapy vs observation only after mastectomy and adjuvant chemotherapy and/or hormonal therapy.

• Compare local regional control in patients treated with these regimens.

• Assess the potential toxic effects of radiotherapy in this patient population.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior systemic hormonal therapy (chemotherapy with or without hormonal therapy vs hormonal therapy alone), prior taxane exposure (yes vs no), and duration of chemotherapy (no chemotherapy vs less than 3 months vs 3-5 months vs 6 months or more). Patients are randomized to one of two treatment arms.

• Arm I: Patients undergo radiotherapy 5 days a week for 5 weeks.

• Arm II: Patients are observed for disease progression. Patients are followed every 6 months for 2 years and then annually for 15 years.

PROJECTED ACCRUAL: A total of 2,500 patients (1,250 per treatment arm) will be accrued for this study within 5 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 98
• Est. completion date: March 2005
• Est. primary completion date: March 2005
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed stage II adenocarcinoma of the breast (T1-2, N1, M0)

• Primary tumor no greater than 5 cm

• At least 1 but no more than 3 positive axillary lymph nodes

• Nodes cannot be positive solely by cytokeratin staining

• No apocrine, adenocystic, or squamous cell carcinomas or sarcomas of the breast

• No bilateral breast cancer

• No active local regional disease

• Must have undergone a modified radical mastectomy with a level I and II with or without a level III axillary dissection (at least 10 nodes examined) within the past 8 months

• Surgical margins negative for invasive and noninvasive ductal carcinoma

• No gross extracapsular disease or residual disease in the axilla

• Microscopic extracapsular extension allowed

• No mastectomy after local failure following lumpectomy

• Must have received adjuvant chemotherapy and/or hormonal therapy after mastectomy

• Hormone receptor status:

• Not specified

PATIENT CHARACTERISTICS:

Age:

• 21 and over

Sex:

• Female

Menopausal status:

• Pre- or post-menopausal

Performance status:

• Zubrod 0-1

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

• No serious medical or psychiatric illness that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior trastuzumab (Herceptin)

Chemotherapy:

• See Disease Characteristics

• No more than 6 weeks since prior adjuvant chemotherapy

• No other prior chemotherapy

• Concurrent adjuvant chemotherapy allowed

Endocrine therapy:

• See Disease Characteristics

• Concurrent adjuvant hormonal therapy allowed

Radiotherapy:

• No prior chest wall or nodal radiotherapy

Surgery:

• See Disease Characteristics

• Breast reconstruction allowed

Other:

• Concurrent registration on another adjuvant chemotherapy or hormonal therapy study is allowed

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Radiation:
• radiation therapy

Procedure:
• surgery
surgery

Locations

Country	Name	City	State
Canada	Cancer Care Ontario-Hamilton Regional Cancer Centre	Hamilton	Ontario

Sponsors (9)

Lead Sponsor	Collaborator
Southwest Oncology Group	American College of Surgeons, Canadian Cancer Trials Group, Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, National Cancer Institute (NCI), North Central Cancer Treatment Group, NSABP Foundation Inc, Radiation Therapy Oncology Group

Country where clinical trial is conducted

Canada,